Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Polymer Based Solubility Enhancement Excipients Market

ID: MRFR/HC/25468-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026
Polymer Based Solubility Enhancement Excipients Market Research Report By Excipient Type (Polymeric Surfactants, Cyclodextrins, Polymers, Phospholipids, Other Excipient Types), By Bioavailability Enhancement Mechanism (Solubilization, Permeation Enhancement, Dissolution Rate Enhancement, Crystal Modification), By Application (Oral, Parenteral, Ophthalmic, Dermal, Other Applications) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Excipient Type (USD Billion)
      1. 4.1.1 Polymeric Surfactants
      2. 4.1.2 Cyclodextrins
      3. 4.1.3 Polymers
      4. 4.1.4 Phospholipids
      5. 4.1.5 Other Excipient Types
    2. 4.2 Healthcare, BY Bioavailability Enhancement Mechanism (USD Billion)
      1. 4.2.1 Solubilization
      2. 4.2.2 Permeation Enhancement
      3. 4.2.3 Dissolution Rate Enhancement
      4. 4.2.4 Crystal Modification
    3. 4.3 Healthcare, BY Application (USD Billion)
      1. 4.3.1 Oral
      2. 4.3.2 Parenteral
      3. 4.3.3 Ophthalmic
      4. 4.3.4 Dermal
      5. 4.3.5 Other Applications
    4. 4.4 Healthcare, BY Region (USD Billion)
      1. 4.4.1 North America
        1. 4.4.1.1 US
        2. 4.4.1.2 Canada
      2. 4.4.2 Europe
        1. 4.4.2.1 Germany
        2. 4.4.2.2 UK
        3. 4.4.2.3 France
        4. 4.4.2.4 Russia
        5. 4.4.2.5 Italy
        6. 4.4.2.6 Spain
        7. 4.4.2.7 Rest of Europe
      3. 4.4.3 APAC
        1. 4.4.3.1 China
        2. 4.4.3.2 India
        3. 4.4.3.3 Japan
        4. 4.4.3.4 South Korea
        5. 4.4.3.5 Malaysia
        6. 4.4.3.6 Thailand
        7. 4.4.3.7 Indonesia
        8. 4.4.3.8 Rest of APAC
      4. 4.4.4 South America
        1. 4.4.4.1 Brazil
        2. 4.4.4.2 Mexico
        3. 4.4.4.3 Argentina
        4. 4.4.4.4 Rest of South America
      5. 4.4.5 MEA
        1. 4.4.5.1 GCC Countries
        2. 4.4.5.2 South Africa
        3. 4.4.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 BASF SE (DE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Evonik Industries AG (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Dow Inc. (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Ashland Global Holdings Inc. (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Solvay SA (BE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 FMC Corporation (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Wacker Chemie AG (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Hercules Inc. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Kraton Corporation (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY EXCIPIENT TYPE
    4. 6.4 US MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    5. 6.5 US MARKET ANALYSIS BY APPLICATION
    6. 6.6 CANADA MARKET ANALYSIS BY EXCIPIENT TYPE
    7. 6.7 CANADA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    8. 6.8 CANADA MARKET ANALYSIS BY APPLICATION
    9. 6.9 EUROPE MARKET ANALYSIS
    10. 6.10 GERMANY MARKET ANALYSIS BY EXCIPIENT TYPE
    11. 6.11 GERMANY MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    12. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
    13. 6.13 UK MARKET ANALYSIS BY EXCIPIENT TYPE
    14. 6.14 UK MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    15. 6.15 UK MARKET ANALYSIS BY APPLICATION
    16. 6.16 FRANCE MARKET ANALYSIS BY EXCIPIENT TYPE
    17. 6.17 FRANCE MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    18. 6.18 FRANCE MARKET ANALYSIS BY APPLICATION
    19. 6.19 RUSSIA MARKET ANALYSIS BY EXCIPIENT TYPE
    20. 6.20 RUSSIA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    21. 6.21 RUSSIA MARKET ANALYSIS BY APPLICATION
    22. 6.22 ITALY MARKET ANALYSIS BY EXCIPIENT TYPE
    23. 6.23 ITALY MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    24. 6.24 ITALY MARKET ANALYSIS BY APPLICATION
    25. 6.25 SPAIN MARKET ANALYSIS BY EXCIPIENT TYPE
    26. 6.26 SPAIN MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    27. 6.27 SPAIN MARKET ANALYSIS BY APPLICATION
    28. 6.28 REST OF EUROPE MARKET ANALYSIS BY EXCIPIENT TYPE
    29. 6.29 REST OF EUROPE MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    30. 6.30 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    31. 6.31 APAC MARKET ANALYSIS
    32. 6.32 CHINA MARKET ANALYSIS BY EXCIPIENT TYPE
    33. 6.33 CHINA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    34. 6.34 CHINA MARKET ANALYSIS BY APPLICATION
    35. 6.35 INDIA MARKET ANALYSIS BY EXCIPIENT TYPE
    36. 6.36 INDIA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    37. 6.37 INDIA MARKET ANALYSIS BY APPLICATION
    38. 6.38 JAPAN MARKET ANALYSIS BY EXCIPIENT TYPE
    39. 6.39 JAPAN MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    40. 6.40 JAPAN MARKET ANALYSIS BY APPLICATION
    41. 6.41 SOUTH KOREA MARKET ANALYSIS BY EXCIPIENT TYPE
    42. 6.42 SOUTH KOREA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    43. 6.43 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    44. 6.44 MALAYSIA MARKET ANALYSIS BY EXCIPIENT TYPE
    45. 6.45 MALAYSIA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    46. 6.46 MALAYSIA MARKET ANALYSIS BY APPLICATION
    47. 6.47 THAILAND MARKET ANALYSIS BY EXCIPIENT TYPE
    48. 6.48 THAILAND MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    49. 6.49 THAILAND MARKET ANALYSIS BY APPLICATION
    50. 6.50 INDONESIA MARKET ANALYSIS BY EXCIPIENT TYPE
    51. 6.51 INDONESIA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    52. 6.52 INDONESIA MARKET ANALYSIS BY APPLICATION
    53. 6.53 REST OF APAC MARKET ANALYSIS BY EXCIPIENT TYPE
    54. 6.54 REST OF APAC MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    55. 6.55 REST OF APAC MARKET ANALYSIS BY APPLICATION
    56. 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. 6.57 BRAZIL MARKET ANALYSIS BY EXCIPIENT TYPE
    58. 6.58 BRAZIL MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    59. 6.59 BRAZIL MARKET ANALYSIS BY APPLICATION
    60. 6.60 MEXICO MARKET ANALYSIS BY EXCIPIENT TYPE
    61. 6.61 MEXICO MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    62. 6.62 MEXICO MARKET ANALYSIS BY APPLICATION
    63. 6.63 ARGENTINA MARKET ANALYSIS BY EXCIPIENT TYPE
    64. 6.64 ARGENTINA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    65. 6.65 ARGENTINA MARKET ANALYSIS BY APPLICATION
    66. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY EXCIPIENT TYPE
    67. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    68. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    69. 6.69 MEA MARKET ANALYSIS
    70. 6.70 GCC COUNTRIES MARKET ANALYSIS BY EXCIPIENT TYPE
    71. 6.71 GCC COUNTRIES MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    72. 6.72 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    73. 6.73 SOUTH AFRICA MARKET ANALYSIS BY EXCIPIENT TYPE
    74. 6.74 SOUTH AFRICA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    75. 6.75 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    76. 6.76 REST OF MEA MARKET ANALYSIS BY EXCIPIENT TYPE
    77. 6.77 REST OF MEA MARKET ANALYSIS BY BIOAVAILABILITY ENHANCEMENT MECHANISM
    78. 6.78 REST OF MEA MARKET ANALYSIS BY APPLICATION
    79. 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. 6.80 RESEARCH PROCESS OF MRFR
    81. 6.81 DRO ANALYSIS OF HEALTHCARE
    82. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. 6.85 HEALTHCARE, BY EXCIPIENT TYPE, 2024 (% SHARE)
    86. 6.86 HEALTHCARE, BY EXCIPIENT TYPE, 2024 TO 2035 (USD Billion)
    87. 6.87 HEALTHCARE, BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2024 (% SHARE)
    88. 6.88 HEALTHCARE, BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2024 TO 2035 (USD Billion)
    89. 6.89 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    90. 6.90 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    91. 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.3.3 BY APPLICATION, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.4.3 BY APPLICATION, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.5.3 BY APPLICATION, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.6.3 BY APPLICATION, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.7.3 BY APPLICATION, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.8.3 BY APPLICATION, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.9.3 BY APPLICATION, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.10.3 BY APPLICATION, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.11.3 BY APPLICATION, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.12.3 BY APPLICATION, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.13.3 BY APPLICATION, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.14.3 BY APPLICATION, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.15.3 BY APPLICATION, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.16.3 BY APPLICATION, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.17.3 BY APPLICATION, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.18.3 BY APPLICATION, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.19.3 BY APPLICATION, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.20.3 BY APPLICATION, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.21.3 BY APPLICATION, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.22.3 BY APPLICATION, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.23.3 BY APPLICATION, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.24.3 BY APPLICATION, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.25.3 BY APPLICATION, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.26.3 BY APPLICATION, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.27.3 BY APPLICATION, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.28.3 BY APPLICATION, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.29.3 BY APPLICATION, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY EXCIPIENT TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY BIOAVAILABILITY ENHANCEMENT MECHANISM, 2025-2035 (USD Billion)
      3. 7.30.3 BY APPLICATION, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Excipient Type (USD Billion, 2025-2035)

  • Polymeric Surfactants
  • Cyclodextrins
  • Polymers
  • Phospholipids
  • Other Excipient Types

Healthcare By Bioavailability Enhancement Mechanism (USD Billion, 2025-2035)

  • Solubilization
  • Permeation Enhancement
  • Dissolution Rate Enhancement
  • Crystal Modification

Healthcare By Application (USD Billion, 2025-2035)

  • Oral
  • Parenteral
  • Ophthalmic
  • Dermal
  • Other Applications